Adicet Bio Q4 2022 net loss $29.9M; cash $257.7M; ADI-001 ORR 75%

Adicet Bio, Inc.

Q4 net loss $29.9M ($0.72 per share) vs $15.8M in Q4 2021; FY net loss $69.8M.
Cash and equivalents $257.7M at Dec 31, 2022; expected runway into H1 2025.
R&D expenses Q4 $25.0M, up 70% YoY; G&A $6.6M, flat.
ADI-001 Phase 1 data: 75% ORR, 69% CR across doses; pivotal study plan in Q2 2023.
IND for ADI-925 (CAd gamma delta T cell) expected H2 2023.

Key facts

Extracted from this filing and checked against the source text.

Earnings Releases SEC 8-K Item 2.02 confidence 0.95

Adicet Bio, Inc. reported for the fourth quarter and year ended December 31, 2022 results: net income Net loss for the three months ended December 31, 2022 was $29.9 million, EPS a net loss of $0.72 per basic and diluted share.

Period: for the fourth quarter and year ended December 31, 2022
Net income: Net loss for the three months ended December 31, 2022 was $29.9 million
EPS: a net loss of $0.72 per basic and diluted share
Result: reported results

Exact text from the filing

Adicet Bio, Inc. announced its financial results for the quarter and year ended December 31, 2022.

View on SEC.gov

Browse all earnings releases →

Adicet Bio, Inc. filing history →

Source: SEC EDGAR

accession 0000950170-23-008122

view filing index on sec.gov

view primary document

Machine-readable: JSON · Markdown · Plain text

This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.